Home › Companies › Emergent BioSolutions Inc. › 2025-2026

Emergent BioSolutions Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Emergent BioSolutions Inc.’s Form 8-K, filed April 30, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.

7Reported items
202Asset managers
1,541Fund votes
April 29, 2026Meeting date

Results at a glance

Meeting of April 29, 2026: 7 items on Emergent BioSolutions Inc.’s Form 8-K, filed April 30, 2026: 4 elected · 3 approved.

Material dissent

3. Approved 60% of votes cast Approved Under 80%
4. Approved 54.8% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Emergent BioSolutions Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Emergent BioSolutions Inc.

These tallies are Emergent BioSolutions Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 30, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Emergent BioSolutions Inc. — official shareholder meeting results, meeting held April 29, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Sujata Dayal	29,593,251	--	--	1,466,690	9,286,731	95%	Elected	—
Elect Director: John Fowler, Jr.	30,647,734	--	--	412,207	9,286,731	99%	Elected	—
Elect Director: Zsolt Harsanyi, Ph.D.	28,672,319	--	--	2,387,622	9,286,731	92%	Elected	—
Elect Director: Joseph Papa	29,271,291	--	--	1,788,650	9,286,731	94%	Elected	—
2. Approved	38,947,477	1,271,938	127,257	--	--	97%	Approved	—
3. Approved	18,187,878	11,988,552	883,511	--	9,286,731	60%	Approved	—
4. Approved	16,972,952	14,023,162	63,827	--	9,286,731	54.8%	Approved	—

Source: Emergent BioSolutions Inc., Form 8-K, filed with the SEC on April 30, 2026 — read the filing on EDGAR.

How asset managers voted at the Emergent BioSolutions Inc. 2025-2026 meeting

Each item below shows how the 202 asset managers that disclosed a Emergent BioSolutions Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Emergent BioSolutions Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Sujata Dayal

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 29,593,251WITHHELD: 1,466,690

Details: description as filed, official tally, votes by 61 asset managers

Description as filed by funds: To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders, each to serve until their respective successors are duly elected and qualified: Sujata Dayal

Emergent BioSolutions Inc.’s own tally for this item (“Elect Director: Sujata Dayal”): 29,593,251 for, 1,466,690 withheld, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All director nominees were elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 12,895,788 for, 46,681 withheld, 4 abstained.

FOR

FOR: 12,895,788ABSTAIN: 4WITHHOLD: 46,681

Largest asset managers voting on “To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders” at Emergent BioSolutions Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,277,537	4	4,138	For
American Century	2,310,609	0	0	For
Charles Schwab	1,622,170	0	0	For
BlackRock	1,326,492	0	0	For
Dimensional	1,082,047	0	0	For
State Street	510,698	0	510	For
Federated Hermes	401,190	0	0	For
PIMCO	332,101	0	0	For
Fidelity	203,544	0	0	For
SEI	184,262	0	0	For
Northern Trust	178,346	0	0	For
Goldman Sachs	144,838	0	0	For
Equitable	87,239	0	33,040	Mixed
TIAA	100,266	0	0	For
QUANTITATIVE MASTER SERIES LLC	85,455	0	0	For
Capitol Series Trust	81,655	0	0	For
AMERICAN BEACON FUNDS	80,650	0	0	For
WisdomTree	79,561	0	0	For
Direxion Shares ETF Trust	67,083	0	0	For
JAMES ADVANTAGE FUNDS	61,660	0	0	For
TARGET PORTFOLIO TRUST	60,200	0	0	For
Pacific Life	55,854	0	0	For
SEI Exchange Traded Funds	54,609	0	0	For
Jackson National	50,649	0	0	For
Russell Investments	47,014	0	0	For

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

2. Elect Director: John Fowler, Jr.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 30,647,734WITHHELD: 412,207

Details: description as filed, official tally, votes by 61 asset managers

Emergent BioSolutions Inc.’s own tally for this item (“Elect Director: John Fowler, Jr.”): 30,647,734 for, 412,207 withheld, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All director nominees were elected and qualified.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 12,942,472 for, 1 abstained.

FOR

FOR: 12,942,472ABSTAIN: 1

Largest asset managers voting on “To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders” at Emergent BioSolutions Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,281,677	1	For
American Century	2,310,609	0	For
Charles Schwab	1,622,170	0	For
BlackRock	1,326,492	0	For
Dimensional	1,082,047	0	For
State Street	511,208	0	For
Federated Hermes	401,190	0	For
PIMCO	332,101	0	For
Fidelity	203,544	0	For
SEI	184,262	0	For
Northern Trust	178,346	0	For
Goldman Sachs	144,838	0	For
Equitable	120,279	0	For
TIAA	100,266	0	For
QUANTITATIVE MASTER SERIES LLC	85,455	0	For
Capitol Series Trust	81,655	0	For
AMERICAN BEACON FUNDS	80,650	0	For
WisdomTree	79,561	0	For
Direxion Shares ETF Trust	67,083	0	For
JAMES ADVANTAGE FUNDS	61,660	0	For
TARGET PORTFOLIO TRUST	60,200	0	For
Pacific Life	55,854	0	For
SEI Exchange Traded Funds	54,609	0	For
Jackson National	50,649	0	For
Russell Investments	47,014	0	For

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

3. Elect Director: Zsolt Harsanyi, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%

FOR: 28,672,319WITHHELD: 2,387,622

Details: description as filed, official tally, votes by 61 asset managers

Emergent BioSolutions Inc.’s own tally for this item (“Elect Director: Zsolt Harsanyi, Ph.D.”): 28,672,319 for, 2,387,622 withheld, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All director nominees were elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 12,743,893 for, 198,575 withheld, 5 abstained.

FOR

FOR: 12,743,893ABSTAIN: 5WITHHOLD: 198,575

Largest asset managers voting on “To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders” at Emergent BioSolutions Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,275,605	5	6,069	For
American Century	2,310,609	0	0	For
Charles Schwab	1,622,170	0	0	For
BlackRock	1,326,492	0	0	For
Dimensional	1,082,047	0	0	For
State Street	510,683	0	525	For
Federated Hermes	401,190	0	0	For
PIMCO	332,101	0	0	For
Fidelity	203,544	0	0	For
SEI	184,262	0	0	For
Northern Trust	0	0	178,346	Withhold
Goldman Sachs	144,838	0	0	For
Equitable	120,279	0	0	For
TIAA	100,266	0	0	For
QUANTITATIVE MASTER SERIES LLC	85,455	0	0	For
Capitol Series Trust	81,655	0	0	For
AMERICAN BEACON FUNDS	80,650	0	0	For
WisdomTree	79,561	0	0	For
Direxion Shares ETF Trust	67,083	0	0	For
JAMES ADVANTAGE FUNDS	61,660	0	0	For
TARGET PORTFOLIO TRUST	60,200	0	0	For
Pacific Life	55,854	0	0	For
SEI Exchange Traded Funds	54,609	0	0	For
Jackson National	50,649	0	0	For
Russell Investments	47,014	0	0	For

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

4. Elect Director: Joseph Papa

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 29,271,291WITHHELD: 1,788,650

Details: description as filed, official tally, votes by 61 asset managers

Emergent BioSolutions Inc.’s own tally for this item (“Elect Director: Joseph Papa”): 29,271,291 for, 1,788,650 withheld, per its Form 8-K filed April 30, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All director nominees were elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 61 asset managers below reported 12,940,537 for, 1,931 withheld, 5 abstained.

FOR

FOR: 12,940,537ABSTAIN: 5WITHHOLD: 1,931

Largest asset managers voting on “To elect four Class II directors to hold office for a term expiring at our 2029 Annual Meeting of Stockholders” at Emergent BioSolutions Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	3,279,742	5	1,931	For
American Century	2,310,609	0	0	For
Charles Schwab	1,622,170	0	0	For
BlackRock	1,326,492	0	0	For
Dimensional	1,082,047	0	0	For
State Street	511,208	0	0	For
Federated Hermes	401,190	0	0	For
PIMCO	332,101	0	0	For
Fidelity	203,544	0	0	For
SEI	184,262	0	0	For
Northern Trust	178,346	0	0	For
Goldman Sachs	144,838	0	0	For
Equitable	120,279	0	0	For
TIAA	100,266	0	0	For
QUANTITATIVE MASTER SERIES LLC	85,455	0	0	For
Capitol Series Trust	81,655	0	0	For
AMERICAN BEACON FUNDS	80,650	0	0	For
WisdomTree	79,561	0	0	For
Direxion Shares ETF Trust	67,083	0	0	For
JAMES ADVANTAGE FUNDS	61,660	0	0	For
TARGET PORTFOLIO TRUST	60,200	0	0	For
Pacific Life	55,854	0	0	For
SEI Exchange Traded Funds	54,609	0	0	For
Jackson National	50,649	0	0	For
Russell Investments	47,014	0	0	For

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

5. To approve an amendment to the Emergent BioSolutions Inc Amended and Restated Stock Incentive Plan to increase the…

No official matchCOMPENSATION

Combines 4 wordings of this item as funds reported it.

56% of fund votes cast · no official result

FORAGAINST

Details: description as filed, votes by 63 asset managers

Description as filed by funds: To approve an amendment to the Emergent BioSolutions Inc Amended and Restated Stock Incentive Plan to increase the number of shares of common stock for the grant of awards under the plan.

The 63 asset managers below reported 7,272,095 for, 5,664,534 against, 7,412 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,272,095AGAINST: 5,664,534ABSTAIN: 7,412

Largest asset managers voting on “To approve an amendment to the Emergent BioSolutions Inc Amended and Restated Stock Incentive Plan to increase” at Emergent BioSolutions Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	3,277,509	4,170	For
American Century	0	2,310,609	Against
Charles Schwab	1,622,170	0	For
BlackRock	1,326,492	0	For
Dimensional	0	1,082,047	Against
State Street	388,026	123,182	Mixed
Federated Hermes	0	401,190	Against
PIMCO	0	332,101	Against
Fidelity	0	203,544	Against
SEI	184,262	0	For
Northern Trust	0	178,346	Against
Goldman Sachs	0	144,838	Against
Equitable	87,239	33,040	Mixed
TIAA	0	100,266	Against
QUANTITATIVE MASTER SERIES LLC	85,455	0	For
Capitol Series Trust	0	81,655	Against
AMERICAN BEACON FUNDS	0	80,650	Against
WisdomTree	0	79,561	Against
Direxion Shares ETF Trust	0	67,083	Against
JAMES ADVANTAGE FUNDS	0	61,660	Against
TARGET PORTFOLIO TRUST	60,200	0	For
Pacific Life	22,398	33,456	Mixed
SEI Exchange Traded Funds	54,609	0	For
Jackson National	0	50,649	Against
Russell Investments	47,014	0	For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

6. TO HOLD, ON AN ADVISORY BASIS, A VOTE TO APPROVE THE 2025 COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

No official match Fund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

58% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST

Details: votes by 201 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 60 asset managers voting on “TO HOLD, ON AN ADVISORY BASIS, A VOTE TO APPROVE THE 2025 COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at Emergent BioSolutions Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	3,281,649	27	3	For
American Century	0	2,310,609	0	Against
Charles Schwab	1,622,170	0	0	For
BlackRock	1,326,492	0	0	For
Dimensional	0	1,082,047	0	Against
State Street	388,535	122,673	0	Mixed
Federated Hermes	401,190	0	0	For
PIMCO	0	332,101	0	Against
Fidelity	193,889	9,655	0	For
SEI	184,262	0	0	For
Northern Trust	178,346	0	0	For
Goldman Sachs	144,838	0	0	For
Equitable	87,239	33,040	0	Mixed
TIAA	100,266	0	0	For
QUANTITATIVE MASTER SERIES LLC	85,455	0	0	For
Capitol Series Trust	0	81,655	0	Against
AMERICAN BEACON FUNDS	0	80,650	0	Against
WisdomTree	0	79,561	0	Against
Direxion Shares ETF Trust	0	67,083	0	Against
TARGET PORTFOLIO TRUST	60,200	0	0	For
Pacific Life	22,398	33,456	0	Mixed
SEI Exchange Traded Funds	54,609	0	0	For
Jackson National	0	50,649	0	Against
Russell Investments	47,014	0	0	For
Lincoln Financial	36,200	8,907	0	Mixed

Fund voting reports, all 60 managers: 8,320,567 for, 4,553,333 against, 6,915 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 160 asset managers voting on “TO HOLD, ON AN ADVISORY BASIS, A VOTE TO APPROVE THE 2025 COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at Emergent BioSolutions Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
American Century	0	2,394,719	0	Against
Charles Schwab	1,622,217	0	0	For
BlackRock	1,569,794	11,239	0	For
State Street	1,242,948	12,876	0	For
ACADIAN ASSET MANAGEMENT LLC	0	882,155	0	Against
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.	0	0	772,771	Abstain
NEW YORK STATE COMMON RETIREMENT FUND	0	513,904	0	Against
PALISADE CAPITAL MANAGEMENT, LP	0	475,003	0	Against
Federated Hermes	447,015	0	0	For
LSV ASSET MANAGEMENT	382,400	0	0	For
Vanguard	366,765	10,806	0	For
GEODE CAPITAL MANAGEMENT, LLC	328,968	0	0	For
O'SHAUGHNESSY ASSET MANAGEMENT, LLC	0	274,106	0	Against
Dimensional	0	269,862	0	Against
Connor, Clark & Lunn Investment Management Ltd.	0	246,220	0	Against
Ancora Advisors LLC	0	243,052	0	Against
SEI	239,150	0	0	For
DE Shaw	0	230,369	0	Against
Northern Trust	220,935	5,580	0	For
Goldman Sachs	158,671	0	0	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	157,449	0	Against
Prudential/PGIM	136,235	0	0	For
Russell Investments	123,877	0	0	For
AQR	0	116,125	0	Against
Brandywine Global Investment Management, LLC	0	109,600	0	Against

Institutional-manager reports, all 160 managers: 7,861,389 for, 6,979,711 against, 783,631 abstained. Showing the 25 largest; see all in the interactive database.

7. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR

Details: description as filed, votes by 61 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

The 61 asset managers below reported 12,940,523 for, 1,949 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 12,940,523AGAINST: 1,949

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Emergent BioSolutions Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	3,279,743	1,934	For
American Century	2,310,609	0	For
Charles Schwab	1,622,170	0	For
BlackRock	1,326,492	0	For
Dimensional	1,082,047	0	For
State Street	511,193	15	For
Federated Hermes	401,190	0	For
PIMCO	332,101	0	For
Fidelity	203,544	0	For
SEI	184,262	0	For
Northern Trust	178,346	0	For
Goldman Sachs	144,838	0	For
Equitable	120,279	0	For
TIAA	100,266	0	For
QUANTITATIVE MASTER SERIES LLC	85,455	0	For
Capitol Series Trust	81,655	0	For
AMERICAN BEACON FUNDS	80,650	0	For
WisdomTree	79,561	0	For
Direxion Shares ETF Trust	67,083	0	For
JAMES ADVANTAGE FUNDS	61,660	0	For
TARGET PORTFOLIO TRUST	60,200	0	For
Pacific Life	55,854	0	For
SEI Exchange Traded Funds	54,609	0	For
Jackson National	50,649	0	For
Russell Investments	47,014	0	For

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

Largest Emergent BioSolutions Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,800,000 shares outstanding at the time of that meeting.

Fund voting reports: top Emergent BioSolutions Inc. shareholders by shares voted on “To approve an amendment to the Emergent BioSolutions Inc Amended and Restated Stock Incentive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	6.34%
2	American Century	4.46%
3	Charles Schwab	3.13%
4	BlackRock	2.56%
5	Dimensional	2.09%
6	State Street	0.99%
7	Federated Hermes	0.77%
8	PIMCO	0.64%
9	Fidelity	0.39%
10	SEI	0.36%

Institutional-manager reports: top Emergent BioSolutions Inc. shareholders by shares voted on “TO HOLD, ON AN ADVISORY BASIS, A VOTE TO APPROVE THE 2025 COMPENSATION OF OUR NAMED EXECUTIVE…”, 2025-2026
#	Asset manager	% of shares outstanding
1	American Century	4.62%
2	Charles Schwab	3.13%
3	BlackRock	3.05%
4	State Street	2.42%
5	ACADIAN ASSET MANAGEMENT LLC	1.70%
6	PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.	1.49%
7	NEW YORK STATE COMMON RETIREMENT FUND	0.99%
8	PALISADE CAPITAL MANAGEMENT, LP	0.92%
9	Federated Hermes	0.86%
10	LSV ASSET MANAGEMENT	0.74%

Reported Emergent BioSolutions Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Emergent BioSolutions Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	8.38%	13F
Oak Hill Advisors, L.P.	6.98%	DEF14A
Vanguard Group	6.86%	13F
Dimensional Fund Advisors	5.32%	13F
STATE STREET CORPORATION	5.21%	13G
American Century ETF Trust	5.17%	13G
Charles Schwab	2.91%	13F
Morgan Stanley	2.23%	13F
D.E. Shaw	1.94%	13F
Goldman Sachs	1.57%	13F

Percentages above are of 51,800,000 shares outstanding, as reported by Emergent BioSolutions Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Emergent BioSolutions Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At Emergent BioSolutions Inc.'s shareholder meeting held April 29, 2026, in the 2025-2026 proxy season, 202 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,541 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Emergent BioSolutions Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — TO HOLD, ON AN ADVISORY BASIS, A VOTE TO APPROVE THE 2025 COMPENSATION OF OUR NAMED EXECUTIVE… — the reporting funds and managers cast 58% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Emergent BioSolutions Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.